Cargando…

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance

Detalles Bibliográficos
Autores principales:	Pascut, Devis, Pratama, Muhammad Yogi, Tiribelli, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336296/ https://www.ncbi.nlm.nih.gov/pubmed/32647566 http://dx.doi.org/10.2217/hep-2020-0010

Ejemplares similares

Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma
por: Pratama, Muhammad Yogi, et al.
Publicado: (2020)

The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer
por: Masadah, Rina, et al.
Publicado: (2021)

Circulatory miRNA as a Biomarker for Therapy Response and Disease-Free Survival in Hepatocellular Carcinoma
por: Pratama, Muhammad Yogi, et al.
Publicado: (2020)

The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and Their Clinical Implications
por: Pascut, Devis, et al.
Publicado: (2020)

HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development
por: Pascut, Devis, et al.
Publicado: (2021)

Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals
por: Cabral, Loraine Kay D., et al.
Publicado: (2022)

Weighted miRNA co-expression networks analysis identifies circulating miRNA predicting overall survival in hepatocellular carcinoma patients
por: Pascut, Devis, et al.
Publicado: (2020)

Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals
por: Pascut, Devis, et al.
Publicado: (2019)

Circulating microRNA Associated to Different Stages of Liver Steatosis in Prader–Willi Syndrome and Non-Syndromic Obesity
por: Pratama, Muhammad Yogi, et al.
Publicado: (2020)

A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients
por: Pascut, Devis, et al.
Publicado: (2019)

Silencing efficacy prediction: a retrospective study on target mRNA features
por: Pascut, Devis, et al.
Publicado: (2015)

Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma
por: Ladju, Rusdina Bte, et al.
Publicado: (2017)

Correction: Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma
por: Ladju, Rusdina Bte, et al.
Publicado: (2018)

Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma
por: Sukowati, Caecilia H. C., et al.
Publicado: (2021)

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
por: Kanda, Tatsuo, et al.
Publicado: (2019)

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
por: Gao, Xiuzhu, et al.
Publicado: (2020)

MiR-3201 as a Prognostic Blood Biomarker for Curative Treatments in Hepatocellular Carcinoma
por: Grisetti, Luca, et al.
Publicado: (2022)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Hosui, Atsushi, et al.
Publicado: (2021)

The Impact of Hepatitis C Virus (HCV) Treatment with Direct-Acting (DAA) on the Incidence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Liver Disease
por: De Comarmond, Charles, et al.
Publicado: (2017)

Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients
por: Salum, Ghada M., et al.
Publicado: (2019)

Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study
por: Ciancio, Alessia, et al.
Publicado: (2023)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
por: Brozzetti, Stefania, et al.
Publicado: (2021)

Molecular network of HCC aggressiveness
por: Kim, Sang Geon, et al.
Publicado: (2015)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma
por: Sukowati, Caecilia HC, et al.
Publicado: (2012)

Bilirubin-Induced Transcriptomic Imprinting in Neonatal Hyperbilirubinemia
por: Llido, John Paul, et al.
Publicado: (2023)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
por: Morisco, Filomena, et al.
Publicado: (2021)

Differences in circulating microRNA signature in Prader–Willi syndrome and non-syndromic obesity
por: Pascut, Devis, et al.
Publicado: (2018)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Treatment of hepatitis C in HIV patients in the new DAA era
por: Soriano, Vicente
Publicado: (2014)

Is DAA Treatment Associated with HBV Reactivation? Results from ERCHIVES
por: Butt, Adeel, et al.
Publicado: (2017)

Treatment of hepatitis C virus genotype 4 in the DAA era
por: Di Biagio, Antonio, et al.
Publicado: (2018)

Repeated double cross-validation applied to the PCA-LDA classification of SERS spectra: a case study with serum samples from hepatocellular carcinoma patients
por: Gurian, Elisa, et al.
Publicado: (2020)

HCC, diet and metabolic factors: Diet and HCC
por: Montella, Maurizio, et al.
Publicado: (2011)

Serum Stem Cell Growth Factor Beta for the Prediction of Therapy Response in Hepatocellular Carcinoma
por: Sukowati, Caecilia H. C., et al.
Publicado: (2018)

Proteome profiling identifies circulating biomarkers associated with hepatic steatosis in subjects with Prader-Willi syndrome
por: Pascut, Devis, et al.
Publicado: (2023)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
por: Izhari, Mohammad Asrar
Publicado: (2023)

Changing Landscape of Liver Transplantation in the Post-DAA and Contemporary ART Era
por: Saeed, Huma, et al.
Publicado: (2022)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View
por: Bozzato, Alessandro Marco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6enqns9kefmgduf4abglv7ouch